12:00 AM
Jan 21, 2013
 |  BioCentury  |  Product Development

Bonding with Amgen

Phase I data for Bind's nanoparticle technology lands Amgen kinase project

Amgen Inc. is betting that Bind Biosciences Inc.'s Accurin nanotechnology can overcome one of the major limitations for kinase inhibitors in cancer: the fact that these drugs affect healthy and cancerous cells equally. The pair partnered this month to see whether the Accurin technology can target an undisclosed kinase inhibitor from Amgen to cancerous cells in solid tumors.

According to Bind President and CEO Scott Minick, if the companies are successful, the compound would be the first tissue- and cellular-targeted kinase inhibitor in the clinic.

"As a class of drugs, kinase inhibitors can hit their intended target, but they also hit the target in healthy cells in addition to tumor cells," he noted. Accurins are tissue- and tumor-specific, which "enables you to maximize efficacy and tolerability."

The Accurin nanoparticles concentrate in cancerous tissues and not healthy tissues because their physical and chemical properties allow them to exit the vasculature via extravasation only in...

Read the full 760 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >